Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2019-12-16 Regulatory Filings
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory notice of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2019-12-16 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Aptabio Therapeutics Inc. covering the period from January 1, 2019, to September 30, 2019. It contains detailed company information, business descriptions, capital changes, and financial governance details, which are characteristic of a comprehensive interim financial report. It is not an announcement of a report (RPA) or a simple regulatory filing (RNS), as it contains substantive financial and operational data. 9M 2019
2019-11-14 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Aptabio Therapeutics Inc. for the period ending June 30, 2019. It contains detailed company information, financial data, business descriptions, and management disclosures, which are characteristic of a comprehensive interim financial report. It is not an announcement or a certification, but the full report itself. H1 2019
2019-08-14 Korean
기타경영사항(특허권취득)(자율공시)(신규한 양이온 리피드를 포함하는 유전자 전달체)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by Aptabio. It details the patent name, content, and utilization plan. Since it does not fit into specific categories like financial reports, M&A, or director dealings, and is a regulatory announcement of a corporate event, it falls under the general regulatory filing category.
2019-08-05 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition and disposal of shares by a major shareholder (LB Investment) in a listed company (AptaBio). This falls under the category of Major Shareholding Notification (MRQ) as it tracks changes in significant ownership levels.
2019-06-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document details the share ownership of major shareholders (Lee Soo-jin, Moon Ho-sang, Moon Sung-hwan) in AptaBio Co., Ltd. following its KOSDAQ listing. It is not an announcement of a report (RPA) but the actual regulatory disclosure of shareholding status. Since it specifically tracks major shareholding thresholds and ownership changes, it falls under the 'Major Shareholding Notification' category.
2019-06-17 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.